Position:
Clinical Associate Professor
Division:
Medical Oncology
Education:
DEC Marianopolis College, Montreal Health Sciences
MDCM McGill University
Recent Publications:
  • Jahnke K, Korfel A, O’Neill B P, Blay JY, Abrey LE, Martus P, Poortmans PM, Shenkier TN et al. International study on low-grade primary central nervous system lymphoma. Ann Neurol 2006; 59(5):755-762.
  • Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, Shenkier TN, Tozer RG, Palmer MJ, Shepherd LE, Liu S, TU D, Goss PE. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study.  Journal of Clinical Oncology. 24(22):3629-35, 2006 Aug 1.
  • Grimm, J. S. Pulido, K. Jahnke, D. Schiff, A. J. Hall, T. N. Shenkier, T. Siegal, N. D. Doolittle, T. Batchelor, U. Herrlinger, E. A. Neuwelt, N. Laperriere, M. C. Chamberlain, J. Y. Blay, A. J. M. Ferreri, A. M. P. Omuro, E. Thiel, and L. E. Abrey. Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Ann. Onc., November 2007; 18: 1851 – 1855.
  • KM Ramadan, T Shenkier, LH Sehn, RD Gascoyne, and JM Connors. A clinicopathological retrospective study of 131 patients with primary bone lymphoma: a population-based study of successively treated cohorts from the British Columbia Cancer Agency. Ann. Onc., January 2007; 18: 129 – 135.
  • Laurie H. Sehn, Brian Berry, Mukesh Chhanabhai, Catherine Fitzgerald, Karamjit Gill, Paul Hoskins, Richard Klasa, Kerry J. Savage, Tamara Shenkier, Judy Sutherland, Randy D. Gascoyne, and Joseph M. Connors. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP.Blood, Mar 2007; 109: 1857 – 1861.
  • Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE. Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer. . N Engl J Med 357:2666, December 27, 2007.
  • Al-Tourah AJ, Gill KK, Chhanabhai M, Hoskins PJ, Klasa RJ, Savage KJ, Sehn LH, Shenkier TN, Gascoyne RD, Connors JM. Population-based analysis of incidence and outcome of transformed non-Hodgkin’s lymphoma. J Clin Oncol. 2008 Nov 10;26(32):5165-9. Epub 2008 Oct 6. PMID: 18838711 [PubMed – indexed for MEDLINE].
  • Grimm SA, McCannel CA, Omuro AM, Ferreri AJ, Blay JY, Neuwelt EA, Siegal T, Batchelor T, Jahnke K, Shenkier TN, Hall AJ, Graus F, Herrlinger U, Schiff D, Raizer J, Rubenstein J, Laperriere N, Thiel E, Doolittle N, Iwamoto FM, Abrey LE. Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report. Neurology. 2008 Oct 21;71(17):1355-60. PMID: 18936428 [PubMed – indexed for MEDLINE].
  • Nancy D. Doolittle, Lauren E. Abrey, Tamara N. Shenkier, Siegal Tali, Jacoline E.C. Bromberg, Edward A. Neuwelt, Carole Soussain, Kristoph Jahnke, Patrick Johnston, Gerald Illerhaus, David Schiff, Tracy Batchelor, Silvia Montoto, Dale F. Kraemer, and Emanuele Zucca; Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report; Blood, Feb 2008; 111: 1085 – 1093.
  • “Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, Flockhart DA, Hancock B, Davidson N, Gralow J, Dickler M, Perez EA, Cobleigh M, Shenkier T, Edgerton S, Miller KD; ECOG 2100. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol. 2008 Oct 1;26(28):4672-8.
  • PMID: 18824714 [PubMed – indexe”
  • Villa, D., J. M. Connors, et al. (2009). “Incidence and risk factors for central nervous  system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy.” Ann Oncol. ( Advance Access published online on October 27, 2009).
  • Yerushalmi, R., M. M. Hayes, Gelmon, K. A. Chia, S. Bajdik, C. Norris, B. Speers, C. Hassell, P. O’Reilly, S. E, Allan, S. Shenkier, T. N et al. (2009). “A phase II trial of a neoadjuvant platinum regimen for locally advanced breast cancer: pathologic response, long-term follow-up, and correlation with biomarkers.” Clin Breast Cancer 9(3): 166-72.